Trial record 4 of 5 for:
SAR441566
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis (SPECIFI-PSO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06073119 |
|
Recruitment Status :
Recruiting
First Posted : October 10, 2023
Last Update Posted : May 9, 2024
|
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details include a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number of study visits will be 7.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Psoriasis | Drug: SAR441566 Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 207 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis |
| Actual Study Start Date : | October 26, 2023 |
| Estimated Primary Completion Date : | April 10, 2025 |
| Estimated Study Completion Date : | May 8, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: SAR441566 dose regimen A
Participants will receive dose regimen A of SAR441566
|
Drug: SAR441566
Tablet |
|
Experimental: SAR441566 dose regimen B
Participants will receive dose regimen B of SAR441566
|
Drug: SAR441566
Tablet |
|
Experimental: SAR441566 dose regimen C
Participants will receive dose regimen C of SAR441566
|
Drug: SAR441566
Tablet |
|
Experimental: SAR441566 dose regimen D
Participants will receive dose regimen D of SAR441566
|
Drug: SAR441566
Tablet |
|
Experimental: SAR441566 dose regimen E
Participants will receive dose regimen E of SAR441566
|
Drug: SAR441566
Tablet |
|
Placebo Comparator: Placebo
Participants will receive SAR441566 matching placebo
|
Drug: Placebo
Tablet |
Primary Outcome Measures :
- Proportion of participants with a 75% or greater PASI score (Psoriasis Area and Severity Index score) improvement (reduction) from baseline (PASI75) at week 12 [ Time Frame: Baseline to Week 12 ]
The PASI is a tool that provides a numeric scoring for participants' overall psoriasis disease state, ranging from 0 (no disease) to 72 (maximal disease). It is a linear combination of percent of surface area of skin (A) that is affected (1 [<10%] to 6 [90% - 100%]) and the severity of erythema [E], induration [I], and desquamation [D] on a scale from 0=no symptoms to 4=very marked over four body regions : head (h), trunk (t), upper extremities (u) and lower extremities (l).
The PASI score is calculated according to the following formula:
PASI = 0.1(Eh+Ih+Dh)Ah + 0.3(Et+It+Dt)At + 0.2(Eu+Iu+Du)Au + 0.4(El+Il+Dl)Al
Secondary Outcome Measures :
- PASI change from baseline to week 12 [ Time Frame: Baseline to week 12 ]
- Proportion of participants with static Psoriasis Global Assessment (sPGA) score 0 (complete clearance) or 1 (minimal disease) from baseline to week 12 [ Time Frame: Baseline to week 12 ]The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions. A lower score indicates less body coverage, with 0 being clear and 1 being almost clear.
- Number of participants with Treatment-Emergent Adverse Events (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs) [ Time Frame: Baseline to week 14 ]Incidence of treatment-emergent AEs (TEAEs), serious AEs (SAEs), and AEs of special interest (AESIs).
- Plasma pre-dose concentrations of SAR441566 [ Time Frame: Week 2 to week 12 ]
- Plasma post-dose concentrations of SAR441566 [ Time Frame: Week 0 to week 12 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
-
Participants with moderate to severe plaque psoriasis for at least 6 months, meeting the following criteria at screening and D1 (prior to randomization):
- PASI ≥ 12 points;
- and sPGA score ≥ 3 points;
- and BSA score ≥ 10%
- Must be a candidate for phototherapy or systemic therapy.
- Total body weight ≥ 50 kg (110 lb) and body mass index (BMI) within the range [18 - 35] kg/m^2 (inclusive)
Exclusion Criteria:
- Other forms of psoriasis than plaque psoriasis, such as guttate psoriasis, psoriatic arthritis, or pustular psoriasis. Nail psoriasis is accepted for inclusion.
- Plaque psoriasis is restricted to scalp, palms, soles, or flexures only.
- Any other skin diseases that can interfere with psoriasis evaluation or treatment response (eg, atopic dermatitis, fungal or bacterial superinfection)
- Other immunologic (autoimmune or inflammatory) disorder, except medically controlled diabetes or thyroid disorder as per Investigator's judgement
- History of recurrent or recent serious infection (eg, pneumonia, septicemia), or infection(s) requiring hospitalization or treatment with IV antiinfectives (antibiotics, antivirals, antifungals, antihelminthics) within 30 days prior to D1, or infections(s) requiring oral antiinfectives (antibiotics, antivirals, antifungals, antihelminthics) within 14 days prior to D1
- Known history of or suspected significant current immunosuppression, including history of invasive opportunistic or helminthic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration
- Participant with personal or family history of long QT syndrome
- History of moderate to severe congestive heart failure (New York Heart Association Class III or IV), or recent cerebrovascular accident, or any other condition in the opinion of the Investigator that would put the participant at risk by participation in the protocol
- History of solid organ transplant
- History of alcohol or drug abuse within the past 2 years
-
History of diagnosis of demyelinating disease such as but not limited to:
- Multiple Sclerosis
- Acute Disseminated Encephalomyelitis
- Balo's Disease (Concentric Sclerosis)
- Charcot-Marie-Tooth Disease
- Guillain-Barre Syndrome
- Human T-lymphotropic virus 1 Associated Myelopathy
- Neuromyelitis Optica (Devic's Disease)
- Planned surgery during the treatment period
- Active malignancy, lymphoproliferative disease, or malignancy in remission for less than 5 years, except adequately treated (cured) localized carcinoma in situ of the cervix or ductal breast, or squamous cell carcinoma, or basal cell carcinoma of the skin
- Any live (attenuated) vaccine within 6 weeks prior to randomization (eg, varicella zoster vaccine, oral polio, rabies) or plan to receive one during the trial
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06073119
Contacts
| Contact: Trial transparency email recommended (Toll free for US & Canada) | 800-633-1610 ext Option 6 | contact-us@sanofi.com |
Locations
Show 52 study locations
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Clinical Sciences and Operations | Sanofi |
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT06073119 |
| Other Study ID Numbers: |
DRI17849 2023-503911-14 ( Registry Identifier: CTIS ) U1111-1290-5787 ( Registry Identifier: ICTRP ) |
| First Posted: | October 10, 2023 Key Record Dates |
| Last Update Posted: | May 9, 2024 |
| Last Verified: | May 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Psoriasis Skin Diseases, Papulosquamous Skin Diseases |